Skip to main content

Table 2 Unique UPRs induced by CPA in GL261(B6) compared to LLC and B16F10 tumors. Shown are the 47 UPRs unique to CPA-treated GL261(B6) tumors identified in Additional file 4: Table S3G, classified into 4 categories based on their functions. Group 1 UPRs are expected to contribute to the anti-tumor response, group 2 UPRs counter the anti-tumor response, and the actions of group 3 UPRs depend on cell context. Only two of the UPRs are associated with the glioma-specific lineage of GL261 tumors (group 4)

From: Metronomic cyclophosphamide activation of anti-tumor immunity: tumor model, mouse host, and drug schedule dependence of gene responses and their upstream regulators

Category Reported function Predicted activation state Molecule type Upstream regulator
1. Facilitate tumor regression by immune-mediated mechanisms or by inhibiting tumor cell survival Activate immune responses Activated Cytokine IL12 (complex), IL7,IL12A,IL12B,CCL11
Enzyme TRAF6
Kinase MAPK8,MAPKAPK2,MAP3K14,RIPK2
Other MOG,TAC1
Transcription regulator TBX21,HMGB1,IRF6,HOXA7
Transmembrane receptor TLR2,TYROBP,CD2,CD14,OLR1,CD86,BTNL2
Inhibit immune responses Inhibited Transcription regulator PRDM1
Neurohormone CORT
Phosphatase DUSP1
Promote tumor cell survival Inhibited Enzyme SCD
Growth factor WISP2
Kinase PRKAA1
Mature microRNA miR-155-5p (miRNAs w/seed UAAUGCU)
Transcription regulator MAX,BCL3
2. Counter tumor regression Inhibit immune respones Activated Enzyme PTGS2
Promote tumor cell survival Activated Enzyme FN1
Kinase FGFR2
3. Postive or negatve regulator of immune response, depending on cell context Activate or inhibit immunity Activated Cytokine CSF2,CXCL8,PF4
G-protein coupled receptor CCR5
Apoptotic factor TRADD
Activate or inhibit immunity Inhibited Enzyme TAB1
Kinase MTOR
Other PTX3
Transcription regulator IRF4
Transporter APOA1
4. Glioma cell lineage Brain development Activated Transcription regulator SIM1,PAX7